Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

LDCT Plus miRNA Bolsters Prevention Efforts

Key clinical point: Adding miRNA testing to low-dose computed tomography lung cancer screening bolsters prevention efforts.

Major finding: Cumulative lung cancer rates were 0.6% for double-negative screening, 3.8% for single-positive screening, and 20.1% for double-positive screening; there were no differences in stage I lung cancers, resection rates, or interval cancer incidence in the 3-year LDCT repeat group.

Study details: The prospective bioMILD study of 4,119 current or former heavy smokers.

Disclosures: Dr. Pastorino and Dr. de Koning each reported having no disclosures.

Citation:

Pastorino U et al. WCLC 2019, Abstract PL02.04.